

Index

- Acquired immunodeficiency syndrome (AIDS), Epstein-Barr virus association, 384–387
- Actinic prurigo, polymorphous light eruption, 54
- Actinic reticuloid reaction, polymorphous light eruption, 54
- Activating protein-1 (AP-1), mycosis fungoides, 289
- Activation/proliferation markers:
 anaplastic large cell lymphoma, 448–449
 defined, 10
- Acute myelogenous leukemia,
 nasal/extranodal natural killer cell/T cell lymphomas, 400–401
- Adhesion markers, follicle center cell lymphoma, 177
- Adnexotropic mycosis fungoides, clinical features, 273, 278–279
- Adnexotropic T cell dyscrasia, case study, 122–123
- Adult T cell leukemia/lymphoma:
 case studies, 322–326
 chronic/smoldering variant, 319–323
 clinical features, 318–319
 pathogenesis, 320–321
 pathology, 319–320
 phenotypic studies, 320
- Alibert variant, mycosis fungoides, 267
- ALK1 antibody, anaplastic large cell lymphoma, 449
- ALK-1 Break apart Probe, defined, 12
- Allergic contact dermatitis:
 clinical features, 33–34
 differential diagnosis, 36
 histomorphology, 34–35
 pathogenesis, 35–36
- Allogeneic bone marrow transplantation, cell-poor vacuolar interface dermatitis, graft-versus-host disease, 43
- Allogeneic hematopoietic stem cell transplantation (all-HSCT), cutaneous T cell lymphoma therapy, 20
- Alopecia, syringolymphoid hyperplasia with, 103–104
- Alopecia mucinosa:
 case study, 120–121
 cell-poor pilotropic T cell dyscrasia, 124
 clinical features, 104–106
 molecular profile, 134
 mucin-poor pilotropic T cell dyscrasia, 118–119
- $\alpha\beta$ T cell subtype:
 subcutaneous panniculitis-like T cell lymphoma, 367–368
- Anaplastic large cell lymphoma, 445
- Angiocentric cutaneous T cell lymphoma of childhood, hydroa vacciniforme-like Epstein-Barr virus associations, 382–384
- Angiocentric immunoproliferative lesion (AIL), lymphomatoid granulomatosis, 429–433
- Angioimmunoblastic lymphadenopathy (AILD):
 case studies, 334–339
 clinical features, 329–331
 Epstein-Barr virus, 381
 light microscopic findings, 331
 molecular studies, 332–333
 pathogenesis, 333
 phenotypic profile, 331–332
- Antibody-dependent cellular immunity, collagen vascular disease, 44–45
- Anti endothelial cell antibodies, collagen vascular disease, 44–45
- Anti-Ro-associated systemic lupus erythematosus:
 interface dermatitis and, 45
 lichenoid dermatitis, 48–49
- AP12 MALT1 Fusion Probe, defined, 12
- Atopic eczema, nummular eczema, differential diagnosis, 38
- Atrophoderma of Pasini and Pierini, morphea pathogenesis, 57
- Atypical lymphocytic lobular panniculitis:
 case studies, 116–117, 125
 clinical features, 106–108
 molecular profile, 134–135, 137
 subcutaneous panniculitis-like T cell lymphoma and, 368–371
- Atypical pigmentary purpura reactions, lymphomatoid tissue reactions, 65–66
- Autoimmune progesterone dermatitis, 41–42
- Baboon syndrome, allergic eczematous drug reaction, 36
- Bacille-Calmette-Guérin vaccine, pityriasis rosea, 37
- Bacterial infection, hydroa vacciniforme-like Epstein-Barr virus associations, 382–384
- bax/bcl-2 system, mycosis fungoides, 288–289
- B-cell chronic lymphocytic leukemia (B-CLL)
 clinical features, 226
 cytogenetic studies, 227–228
 molecular studies, 227
 morphology, 226–227
 pathogenesis, 228
 phenotype, 227

The Cutaneous Lymphoid Proliferations: A Comprehensive Textbook of Lymphocytic Infiltrates of the Skin, by Cynthia M. Magro, A. Neil Crowson, and Martin C. Mihm
Copyright © 2007 John Wiley & Sons, Inc.

- B cell markers, defined, 9–10
- Bcl-1 marker:
defined, 9
mantle cell lymphoma, 248
- bcl-2IgH Fusion probe, defined, 12
- Bcl-2 marker:
defined, 9–10
diffuse large B cell lymphoma, 192–199
follicle center cell lymphoma
- BCL-6 protein, defined, 10
- BCL-10 marker, defined, 10
- Benign disorders:
clonality and, 30–31
lymphocytic infiltrates:
autoimmune disease, diffuse/nodular infiltrates, 55–59
basic principles, 33
cell-poor vacuolar interface dermatitis, 40–46
diffuse/nodular infiltrates without atypia, 52–55
lichenoid interface dermatitis, 46–52
spongiotic and eczematous dermatitis, 33–378
- Bexarotene, cutaneous T cell lymphoma therapy, 17
- BF-1 antibody, defined, 8
- Blastic/blastoid NK cell lymphoma, epidemiology, 406
- Bone marrow involvement, mycosis fungoides, 286
- Borderline CD30-positive lymphoproliferative disorders, 445
- Borrelia burgdorferi*:
marginal zone lymphomas, 146
morphea pathogenesis, 58
- Capillary electrophoresis, polymerase chain reaction products, 28–29
- Cardiovascular system, mycosis fungoides, 285
- Carmustine (BCNU), cutaneous T cell lymphoma therapy, 20–21
- Castleman disease:
cell-poor vacuolar interface dermatitis, 44
defined, 8
lymphomatoid granulomatosis, 430–433, 432–436
lymphomatoid tissue reactions, 68
mycosis fungoides, 267–268, 286–288
agranular CD4-positive CD56-positive hematodermic neoplasm, 406
pityriasis lichenoides chronica, 102–103
T cell prolymphocytic leukemia (T-PLL), 357
- CD5 antigen:
B-cell chronic lymphocytic leukemia (B-CLL), 228
defined, 8
diffuse large B cell lymphoma, 196
marginal zone lymphoma
mycosis fungoides, 286–288
- CD7 antigen:
CD8 T cell lymphoproliferative disease, 346
cutaneous lymphoid dyscrasia, 94
defined, 8
large plaque parapsoriasis, 95–96
lymphomatoid tissue reactions, 654–668
mycosis fungoides, 286–288
- CD8 antigen:
allergic contact dermatitis, 34
anaplastic large cell lymphoma, 465
cell-poor vacuolar interface dermatitis, 44
defined, 8–9
 $\gamma\delta$ T cell lymphoma, 261–264
lymphomatoid granulomatosis, 430–433
lymphomatoid papulosis, 442–445
mycosis fungoides, 267–268
CD8 variants of lymphoma: 343–345
nasal/extranodal natural killer cell/T cell lymphomas, 401–405
pityriasis lichenoides chronica, 102–103
subcutaneous panniculitis-like T cell lymphoma, 370
- CD8 T cell lymphoproliferative disease:
basic characteristics, 343–345
case studies, 349–363
CD30-positive disorder, 460–462
drug therapy and, 348
histomorphology, 345–346
lymphomatoid papulosis variants, 346–347
NK/T cell lymphomas, 414–415
phenotypic profile, 346
primary cutaneous lymphoma, 343–345
pseudolymphomas, 348
- CD10 antigen:
angioimmunoblastic lymphadenopathy, 331–332
defined, 9
diffuse large B cell lymphoma, 196–197
follicle center cell lymphoma, 176
marginal zone lymphomas, 148
precursor B lymphoblastic lymphoma/leukemia, 200
- CD15 marker, defined, 10
- CD16 marker, defined, 9
- CD19 antigen, defined, 9
- CD20 antigen:
defined, 9
- CD21 network:
angioimmunoblastic lymphadenopathy, 331–332
follicle center cell lymphoma, 176
marginal zone lymphoma, 148
- CD22 antigen, defined, 9
- CD23 antigen:
mantle cell lymphoma
- CD23 expression:
chronic lymphocytic leukemia
follicle center cell lymphoma, 176
marginal zone lymphoma, 144–146
differential diagnosis, 147–148
- CD25 antigen, defined, 10
- CD25-positive cutaneous T cell lymphoma, immunotoxin therapy, 17
- CD29 markers, intravascular lymphoma, 221
- CD30 antigen:
atypical pigmentary purpura reactions, 65–66
cutaneous T cell lymphoma therapy, 14–15
defined, 10
diffuse large B cell lymphoma, 196
lymphomatoid granulomatosis, 432–433
lymphomatoid tissue reactions, 68
- CD30-based lymphomas:
EORTC classification, 3–6
primary cutaneous Hodgkin lymphoma, 475–479
- CD30-negative large cell T cell lymphoma:
case studies, 312, 314
clinical features, 300–303
- CD30-positive lymphoproliferative disease:
borderline disease, 445
case studies, 310–311, 313, 451–470
CD8 lymphomatoid papulosis, 444–445
classification, 300–303
cutaneous anaplastic large cell lymphoma, 445–450
epidemiology, 439–440
large B cell lymphoma, 450–451
lymphomatoid papulosis, 440–445
clinical features, 440–441
cytogenetics, 444
pathology, 441–443
phenotypic and molecular studies, 443–444
molecular and cytogenetic studies, 468–470
type A variant, 458–459
type B variant, 458–459
type C variant, 456–457
- CD34 antigen, defined, 10
- CD43 antigen:
defined, 8, 10
diffuse large B cell lymphoma, 196
- CD44 markers, anaplastic large cell lymphoma, 449
- CD45 marker:
CD8 T cell lymphoproliferative disease, 346
mycosis fungoides, 287–288
- CD52 antibody, 9
- CD54 markers, intravascular lymphoma, 221
- CD56 markers:
defined, 9
lymphomatoid granulomatosis, 432–433
nasal/extranodal natural killer cell/T cell lymphomas, 406
CD4 subset, 409
epidemiology, 401–402
subcutaneous panniculitis-like T cell lymphoma, 370
- CD62L selectins:
defined, 8
CD8 T cell lymphoproliferative disease, 346
cutaneous lymphoid dyscrasia, 94

- large plaque parapsoriasis, 95–96
lymphomatoid tissue reactions, 65–68
CD68 marker, defined, 10
CD71 antigen, defined, 10
CD79 marker, diffuse large cell B lymphoma, 195–196
CD123 antigen, defined, 10
CD138 markers, 9
Cell-poor vacuolar interface dermatitis:
 collagen vascular disease, 44–45
 erythema multiforme, 40–42
 Gianotti-Crosti syndrome, 42
 graft-versus-host disease, 42–44
 morbilliform viral exanthem and drug eruption, 44
Centroblasts, follicle center cell lymphoma, 175
Chemotherapy, cutaneous T cell lymphoma, topical therapy, 20–21
Chronic active EBV infection (CAEBV), hydroa vacciniforme-like Epstein-Barr virus associations, 383–384
Chronic lymphocytic leukemia
 B-cell type, 18
 clinical features, 226
 cytogenetic studies, 227–228
 molecular studies, 227
 morphology, 226–227
 pathogenesis, 228
 phenotype, 227
 follicular mucinosis, 85
 mantle cell lymphoma, 249
 molecular and cytogenetic studies, 244–245
 skin infiltration, 231–233, 236–238
 squamous cell carcinoma, 234–235
 T-cell type:
 clinical features, 228–229
 cytogenetics, 230
 differential diagnosis, 230
 light microscopic analysis, 229
 phenotypic abnormalities, 229–230
 prolymphocytic leukemia, 239–240, 242–243
 skin involvement, 241
Classification schemes for lymphoma, 1–6
 See also specific classification scheme
Clonality assessment in prelymphomatous and reactive states
 collagen vascular disease, 87
 lupus erythematosus profundus (LEP), 88
 lymphocytoma cutis, 71
 lymphomatoid granulomatosis, 432
 lymphomatoid tissue reactions, 66–67
 dermatitis, 86
 drug reactions, 79
 polyclonal drug reactions, 80
 vascular reactions, 84
 pigmented purpuric dermatosis, 100
 pityriasis lichenoides chronica, 102–103
 polymerase chain reaction:
 basic principles, 25
 design criteria, 27
Clusterin, anaplastic large cell lymphoma, 449
c-MYC oncogene, diffuse large B cell lymphoma and T cell prolymphocytic leukemia, 197
Collagen vascular disease:
 antibody-dependent cellular immunity and/or anti endothelial cell antibodies, 44–45
 clonality assessment, 87
 lymphomatoid tissue reactions:
 lupus erythematosus profundus, 69–70
 lymphocytoma cutis, 70–71
 lymphomatoid lupus erythematosus, 68–69
 pathogenesis, 69
 primary cutaneous plasmacytosis, 71–72
 viral-associated lymphomatoid dermatitis, 70
Complementary determining region (CDR), immunoglobulin H receptor structure, 26
Complement receptors, hydroa vacciniforme-like Epstein-Barr virus associations, 384
Connective tissue disease, lichenoid syndromes, 48–51
Consensus sequence, immunoglobulin H receptor structure, 26
Coup de sabre lesions, morphea, 57
Cutaneous anaplastic large cell lymphoma, CD30-positive lymphoproliferative disorders, 445–450
Cutaneous lymphocyte antigen (CLA):
 adult T cell leukemia/lymphoma, 320
 cutaneous lymphoid dyscrasia, 94
 defined, 9
 mantle cell lymphoma, 250
 mycosis fungoides, 287–288
 precursor B lymphoblastic lymphoma/leukemia, 200
Cutaneous lymphoid dyscrasia (CLD):
 atypical lobular panniculitis, 106–108
 hypopigmented mycosis fungoides, 96–97
 idiopathic follicular mucinosis/alopecia mucinosa, 104–106
 large plaque parapsoriasis, 94–96
 pigmented purpuric dermatosis, 97–100
 pityriasis lichenoides chronica, 100–103
 precursor lesions, 93–94
 syringolymphoid hyperplasia with alopecia, 103–104
Cutaneous mantle cell lymphoma:
 case studies, 252–256
 clinical features, 248–249
 cytogenetic profile, 250–251
 light microscopic findings, 249
 molecular studies, 250
 pathogenesis, 251
 phenotypic profile, 249–250
Cutaneous T cell lymphoma (CTCL). *See also* Primary cutaneous lymphomas
 advanced stage therapeutic goals, 15
 basic characteristics, 14–15
 CD8 T cell lymphoproliferative disease, 344–345
 cytotoxic chemotherapy, 18
 diagnostic work-up and staging, 15
 epidermotropic cytotoxic lymphoma, 349–354
 extracorporeal photopheresis, 15–16
 granulomatous slack skin, 273
 immunotoxins, 17
 interferons, 16
 investigational therapies, 18–20
 allogeneic hematopoietic stem cell transplantation, 20
 histone deacetylase inhibitors, 19–20
 monoclonal antibodies, 19
 toll-like receptor agonists and cytokines, 19
 monoclonal antibodies, 17–18
 mycosis fungoides, 285–289
 post-transplant lymphoproliferative disease, 387–388
 precursor lesions, 93–94
 primary small/mixed pleomorphic variant:
 case studies, 305–314
 clinical features, 300–303
 cytogenetics, 305, 315
 differential diagnosis, 305
 molecular profiles, 315
 pathology/light microscopic findings, 303–304
 phenotypic profile, 304–305
 retinoids, 16–17
 Sézary syndrome, 274–285
 skin-directed therapies, 20–22
Cyclin D1 IgH Fusion Probe, defined, 12
Cyclosporine, Epstein-Barr virus-associated B cell lymphoma, 388–389
Cytogenetics:
 anaplastic large cell lymphoma, 449
 B-cell chronic lymphocytic leukemia (B-CLL), 227–228
 CD30-positive lymphoproliferative disease, 468–470
 diffuse large B cell lymphoma, 196
 follicle center cell lymphoma, 177, 190
 hydroa vacciniforme-like Epstein-Barr virus associations, 383–384
 lymphocyte-predominant Hodgkin lymphoma, 478
 lymphomatoid papulosis, 444
 mantle cell lymphoma, 250–251, 256
 marginal zone lymphomas, 147
 mycosis fungoides, 288, 292–296
 nasal/extranodal natural killer cell/T cell lymphomas, 405–406
 precursor B lymphoblastic lymphoma/leukemia, 200, 213–215
 primary cutaneous Hodgkin lymphomas, 484–485
 primary cutaneous small/medium sized pleomorphic T cell lymphoma, 305, 315

- Cytogenetics: (*Continued*)
 T cell prolymphocytic leukemia (T-PLL), 230, 244–245
- Cytokines:
 angioimmunoblastic lymphadenopathy, 333
 cutaneous T cell lymphoma therapy, toll-like receptor agonists, 19
- Cytomegalovirus (CMV), cutaneous T cell lymphoma therapy, 18
- Cytoplasmic granularity, nasal/extranodal natural killer cell/T cell lymphomas, 403–404
- Cytotoxic chemotherapy, cutaneous T cell lymphoma therapy, 18
- Cytotoxic molecule expression, mycosis fungoides, 286–288
- Cytotoxic protein markers, defined, 9
- Cytotoxic pseudolymphoma, CD8 T cell lymphoproliferative disease, 348
- phenotypic profile, 66
 polyclonal drug reactions, 80
 morphea histopathology, 57
 pityriasis rosea, 37
- Dutcher body formation, marginal zone lymphomas, 142–144
- Dysproteinemia. *See* Angioimmunoblastic lymphadenopathy (AILD)
- Eczematoid purpura of Doucas and Kapetankis, clinical features, 97–99
- Eczematous dermatitis:
 allergic contact dermatitis, 33–37
 pathogenesis, 35–36
 subacute conditions, 38–40
 tissue reactions, 37–38
- Enteropathy type T cell lymphoma, clinical features, 260–261
- Eosinophilia-myalgia syndrome, morphea histopathology, 57
- Epidermotropism:
 CD8 T cell lymphoproliferative disease, 345, 349–354
 mycosis fungoides, 278–279
- Epstein-Barr Virus-Associated Latent Small Nuclear RNA (EBER):
 defined, 11
 hydroa vacciniforme-like Epstein-Barr virus associations, 383–384
 nasal/extranodal natural killer cell/T cell lymphomas, 404
- Epstein-Barr Virus (EBV):
 CD30-positive large B cell lymphoma, 467
 lymphocyte-predominant Hodgkin lymphoma, 479
 lymphomatoid granulomatosis, 429–436
 lymphoproliferative disease:
 B cell iatrogenic immune dysregulation, 384–389
 case studies, 390–394
 epidemiology, 381–382
 hydroa vacciniforme variant, 382–384
 nasal/extranodal natural killer cell/T cell lymphomas, 399–401, 406–409
 blastic/blastoid variants, 406
 CD4 subset, 408–409
 chronic granular lymphocytosis/large granular cell leukemia, 407–409
 panniculitis-like variant, 406–407
 plasmablastic lymphoma, 386–387, 390–391
 primary cutaneous Hodgkin lymphomas, 476–479
 subcutaneous panniculitis-like T cell lymphoma, 370–371
- Eruptive dermatofibromas, marginal zone lymphomas:
 molecular studies, 165–166
 phenotypic profiles, 144–145
- Erythema annulare centrifugum (EAC):
 features and pathology, 39–40
 perivascular lymphocytic infiltrates, 54
- Erythema chronicum migrans:
 features and pathology, 40
 gyrate erythemas, 54–55
- Erythema gyratum repens:
 features and pathology, 40
 manifestation, 55
- Erythema marginatum:
 features and pathology, 40
 manifestation, 55
- Erythema multiforme, clinical features and pathology, 40–42
- Erythroderma:
 mycosis fungoides, clinical features, 267–268
 pityriasis lichenoides chronica, 102–103
 Sézary syndrome (SS), 274–285
- Erythrophagocytosis, subcutaneous panniculitis-like T cell lymphoma, 369–370
- European BIOMED-2 collaborative study:
 clonality, 25
 PCR clonality determination and detection, 29–30
- European Organization for the Research and Treatment (EORTC):
 diffuse large B cell lymphoma, 193–194
 lymphoma classification, 2–6
 primary cutaneous lymphomas, 173–174
 Sézary syndrome (SS), 274–285
 subcutaneous panniculitis-like T cell lymphoma, 366–368
- Extracorporeal photopheresis (ECP), cutaneous T cell lymphoma therapy, 15–16
 skin-directed agents, 22
- Extracutaneous dissemination, mycosis fungoides, 271, 285–289
 cytogenetic abnormalities, 288
 gene rearrangement profile, 288
 pathogenesis, 288–289
 phenotypic profile, 286–288
- Family-specific sequence, immunoglobulin H receptor structure, 26
- Fas ligand:
 mycosis fungoides, 288–289
 subcutaneous panniculitis-like T cell lymphoma, 370
- Fatal panniculitis, defined, 366–367
- Fluorescent in-situ hybridization (FISH), defined, 11–12
- Follicle center cell lymphoma. *See also* Diffuse large B cell lymphoma
 clinical features, 173–174
 cytogenetics, 177, 190
 large cell type, 181–183
 mixed cell case vignettes, 178–180, 184–189
 molecular studies, 176, 190
 pathogenesis, 176–177
 pathology, 174–175
 phenotypic profile, 176
 prognosis, 177
- Follicular mucinosis:
 clinical features, 104–106
 lymphocytic leukemia, drug reactions, 85
- Follicular mycosis fungoides:
- Delayed dermal hypersensitivity, allergic contact dermatitis, 35
- D'emblee mycosis fungoides, clinical features, 302–303
- Denileukin diftitox, cutaneous T cell lymphoma therapy, 17
- Dermatomyositis:
 antibody-dependent cellular immunity, 45–46
 erythema multiforme differential diagnoses, 41–42
- Dermatophytid, pityriasis rosea, 37
- Diffuse histiocytic lymphoma, classification scheme, 1
- Diffuse large B cell lymphoma:
 case studies, 206–208
 classification, 194
 clinical features, 192–194
 cytogenetics, 196
 differential diagnosis, 197–198
 molecular studies, 196
 monomorphic post-transplant lymphoproliferative disease, 387
 pathogenesis, 196–197
 pathology, 194–195
 phenotype, 195–196
- Drug reactions:
 CD8 T cell lymphoproliferative disease, 348
 case studies, 362
 follicular mucinosis, lymphocytic leukemia, 85
 lichen planus, 47–48
 hypersensitivity case study, 76–77
 lymphocytoma cutis, 75
 lymphomatoid tissue:
 clinical features, 64–65
 clonality assessment, 79
 endogenous immune dysregulation, 73
 histopathology, 65–66
 molecule profile, 66–67
 pathogenetic basis, 67–68

- cytomorphology, 283–285
patch formation, 268–270
- Folliculolymphoid hyperplasia, cytomorphology, 285
- Folliculotropic mycosis fungoides, clinical features, 272
- Fox P3 antibody, 9
- Framework regions (FRs), immunoglobulin H receptor structure, 26
- $\gamma\delta$ T cell subtype:
case studies, 264–265
clinical features, 259–261
molecular studies, 263
morphology, 261–262
phenotype, 262
subcutaneous panniculitis-like T cell lymphoma, 367–370
ultrastructural analysis, 263
- Gastrointestinal involvement, mycosis fungoides, 285
- Gemcitabine, cutaneous T cell lymphoma therapy, 18
- Gene rearrangement profile, mycosis fungoides, 288
- Gianotti-Crosti syndrome:
clinical features and pathology, 42
pityriasis rosea differential diagnosis, 36–37
- Giant follicular lymphoid hyperplasia, clinical features, 148–149
- Glucocorticoid -induced tumor necrosis factor receptor family related protein (GITR), adult T cell leukemia/lymphoma, 321
- Gougerot-Blum purpura, 97–99
- Graft-*versus*-host disease:
cell-poor vacuolar interface dermatitis, 42–44
lichenoid dermatitis, 51–52
morphea histopathology, 57
- Granular lymphocytes (GLs), NK/T cell lymphomas, 407–408
- Granulocytic sarcoma, precursor B lymphoblastic lymphoma/leukemia, 200–202, 211–212
- Granulomatous eccrinotropic lymphomatoid papulosis, pathology, 442–443
- Granulomatous mycosis fungoides, clinical features, 273
- Granzyme B:
mycosis fungoides, 286–288
primary cutaneous aggressive CD8 epidermotropic T cell lymphoma
subcutaneous panniculitis-like T cell lymphoma, 370
- Gyrate erythemas, clinical features and pathology, 54–55
- Hemophagocytic syndrome, hydroa vacciniforme-like Epstein-Barr virus associations, 382–384
- Hepatitis C virus:
marginal zone lymphomas, 146–147
subcutaneous panniculitis-like T cell lymphoma, 370
- Hepatobiliary disease, lichenoid dermatitis, 47–48
- Hepatosplenic T cell lymphoma, clinical features, 259–261
- Hematodermic neoplasms,
nasal/extranodal natural killer cell/T cell lymphomas, 406–409, 416–420, 423
- Herpes-associated erythema multiforme, pathogenesis, 42
- HTLV-1 detection, basic technique, 11
- Histone deacetylase inhibitors (HDACi), cutaneous T cell lymphoma therapy, 19–20
- HLA-DR antigen, defined, 10
- Hodgkin lymphomas:
lymphomatoid papulosis, 442–443
primary cutaneous variants:
case studies, 480–483
classic subtypes, 477
clinical features, 475–476
cytogenetics, 478
histogenesis, 478–479
lymphocyte-predominant variant, 477
molecular and phenotype profiles, 478
- Human herpesvirus 7 (HHV-7), pityriasis rosea, 36–67
- Human herpesvirus 8 (HHV-8):
angiimmunoblastic lymphadenopathy, 333
Castleman's disease, 148–149
plasmablastic lymphoma variant, 386–387, 390–391
- Human immunodeficiency virus (HIV), CD8 pseudolymphoma, 348, 360–361
- Human T cell lymphotropic retrovirus (HTLV-1) genes:
adult T cell leukemia/lymphoma, 318–321
mycosis fungoides, 288
post-transplant lymphoproliferative disease, 387–388
- Hydroa vacciniforme:
Epstein-Barr virus associations, 382–384
polymorphous light eruption, 54
- Hypopigmented epitheliotropic T cell dyscrasia, clinical features, 96–97
- Hypopigmented large plaque parapsoriasis:
clinical features, 96–97
molecular profile, 130
- Hypopigmented mycosis fungoides, clinical features, 96–97
- Iatrogenic immune dysregulation
EBV-associated B cell lymphoproliferative disease:
epidemiology, 384–385
monomorphic PTL, 385–386
diffuse large B cell lymphoma, 387
plasmablastic lymphoma, 386–387
- plasmacytic marginal zone lymphoma, 387
plasmacytic hyperplasia, 385
polymorphic PTL, 385
- Idiopathic erythroderma:
molecular profile, 131
pityriasis lichenoides chronica, 102–103
- Id reaction, 37
- Imiquimod, cutaneous T cell lymphoma therapy, 21
- Immune reactions, polymorphous light eruptions, 52–54
- Immunocytomas, marginal zone lymphomas:
clinical features, 142
phenotypic profiles, 144–145
- Immunofluorescent analysis:
lupus erythematosus profundus, 70
subacute cutaneous lupus erythematosus, 50
- Immunoglobulin genes:
marginal zone lymphomas, 145–146
molecular profiles, 167
molecular diagnostic techniques, basic principles, 25
receptor structure, 26–27
- Immunoglobulin heavy (IgH) gene:
receptor structure, 26–27
- Immunotoxins, cutaneous T cell lymphoma therapy, 17
- Incipient pilotropic T cell dyscrasia, light microscopic findings, 105
- Intercellular adhesion markers (ICAM):
diffuse large B cell lymphoma, 197
follicle center cell lymphoma, 177
mycosis fungoides, 289
- Interface dermatitis, cell-poor vacuolar variants, 40–45
- Interferon- α , cutaneous T cell lymphoma therapy, 16
- Interferon- γ , lymphomatoid papulosis, 444–445
- Interleukin-2, cutaneous T cell lymphoma therapy, 17
- Interleukin-12, cutaneous T cell lymphoma therapy, 19
- International Working Formulation, lymphoma classification, 1–3
- Interstitial granulomatous drug reaction, clinical features, 63–65
- Intravascular lymphoma:
case studies, 222–223
clinical features, 219–220
light microscopy, 220
pathogenesis, 221
phenotypic profiles, 220–221
- Investigational therapies, cutaneous T cell lymphoma, 18–20
allogeneic hematopoietic stem cell transplantation, 20
histone deacetylase inhibitors, 19–20
monoclonal antibodies, 19
toll-like receptor agonists and cytokines, 19

- Jessner's lymphocytic infiltrate of the skin, clinical features and pathology, 58–59
- JUNB amplification, mycosis fungoides, 289
- Juvenile springtime eruption, differential diagnosis, 54
- Ketron-Goodman mycosis fungoides variant, clinical features, 273
- Ki-1 lymphoma, CD30-positive lymphoproliferative disorders, 445–450
- Ki-67 antibody: defined, 10 subcutaneous panniculitis-like T cell lymphoma, 370–371
- Kiel classification for lymphoma, 1–2 marginal zone lymphomas, 142
- Killer inhibitory receptor, nasal/extranodal natural killer cell/T cell lymphomas, 405
- Killer receptor p140/KIR3DL2 (KIR), Sézary syndrome, 274–285
- Labial herpes, primary cutaneous plasmacytoma, 149–150
- Large cell type follicle center cell lymphoma, 181–183
- Large granular cell leukemia, NK/T cell lymphomas, 407–408
- Large granular lymphocytic leukemia: cytotoxic granule expression, 344–345 hydroa vacciniforme-like Epstein-Barr virus associations, 382–384
- Large plaque parapsoriasis (LPP): differential diagnosis, 96 epidemiology, 94–95 light microscopic findings, 95–96 molecular profile, 132–133 mycosis fungoides, 295
- Latent membrane proteins (LMPs), Epstein-Barr virus-associated B cell lymphoma, 388–389
- Lichen aureus, clinical features, 97–98
- Lichenoid dermatitis: clinical features, 46 connective tissue disease, 48–51 drug reactions, 76–77 graft-versus-host disease, 51–52 hepatobiliary disease, 47–48 histopathology, 47 pathogenesis, 46–47 photoallergic pathology, 37–38
- Lichenoid mycosis fungoides, 274–285
- Lichen planus, features and pathogenesis, 46–48
- Lukes-Collins classification system, lymphoma, 1–2
- Lupus erythematosus profundus (LEP): clinical features and pathogenesis, 69–70 subcutaneous nodules, 88 subcutaneous panniculitis-like T cell lymphoma, differential diagnosis, 369–370
- Lyme disease, interface dermatitis and, 45
- Lymph node assessment: angioimmunoblastic lymphadenopathy, 334–339 mycosis fungoides, 282–285 subcutaneous panniculitis-like T cell lymphoma, 367–368
- Lymphocyte-predominant Hodgkin lymphoma, 477–478
- Lymphocytic infiltrates: autoimmune disease, diffuse/nodular infiltrates, 55–59 basic principles, 33 cell-poor vacuolar interface dermatitis, 40–45 classification scheme, 34 diffuse/nodular infiltrates without atypia, 52–55 lichenoid interface dermatitis, 46–52 spongiotic and eczematous dermatitis, 33–37 spongiotic and eczematous tissue reactions, 37–38 subacute eczematous dermatitis, 38–40
- Lymphocytic leukemia, follicular mucinosis, 85
- Lymphocytoma cutis: antidepressant therapy, 75 clinical features, 70–71 drug reactions, T-cell-rich infiltrates, 78 lymphomatoid tissue reactions, 63–66 panniculitis-like T-cell lymphoma, 74 T-cell-rich diffusion, 81–83
- Lymphoma classifications: Kiel, Lukes-Collins and working formulation, 1–2 lymphomatoid papulosis features and, 440–441 WHO, REAL, and EORTC classifications, 2–6
- Lymphomatoid granulomatosis: clinical features, 430–431 clonality studies, 432 differential diagnosis, 432–433 epidemiology, 429–430 Epstein-Barr virus, 381 histogenesis, 432–433 histopathology, 431–432
- Lymphomatoid hypersensitivity reaction: allergic contact dermatitis, 35–36 dermatitis, 86 endogenous immune dysregulation, 73
- Lymphomatoid lupus erythematosus, lymphomatoid tissue reactions, 68–69
- Lymphomatoid papulosis: CD8 T cell lymphoproliferative disease, 346–347 case study, 358–359 clinical features, 440–441 cytogenetics, 444 pathology, 441–443 phenotypic and molecular studies, 443–444
- Lymphomatoid tissue reactions: basic principles, 63–64 collagen vascular disease: lupus erythematosus profundus, 69–70 lymphocytoma cutis, 70–71 lymphomatoid lupus erythematosus, 68–69 pathogenesis, 69 primary cutaneous plasmacytosis, 71–72 viral-associated lymphomatoid dermatitis, 70
- drug eruptions: clinical features, 64–65 histopathology, 65–66 molecule profile, 66–67 pathogenetic basis, 67–68 phenotypic profile, 66
- Lymphomatoid vascular reaction, clinical features, 65–66
- Lymphoproliferative disease of granular lymphocytes (LDGLs), NK/T cell lymphomas, 407–408
- Majocchi's purpura, clinical features, 97–99
- Malignancy, clonality and, 30–31
- MALT1 Break apart Probe, defined, 12
- MALT1 IgH Fusion Probe, defined, 12
- Mantle cell lymphoma: blastoid features, 252–253 case studies, 252–256 chemotherapeutic intervention, 255 clinical features, 248–249 cytogenetic profile, 250–251 diffuse infiltrates, 254 light microscopic findings, 249 molecular studies, 250 pathogenesis, 251 phenotypic profile, 249–250
- Marginal zone lymphoma: classical cutaneous involvement, 154–162 clinical features, 141–142 cytogenetic abnormalities, 147 differential diagnosis, 147–148 Epstein-Barr virus, 392–393 molecular studies, 145 monomorphic post-transplant lymphoproliferative disease, 387 pathogenesis, 145–146 pathology, 142–144 phenotypic profile, 144–145 primary cutaneous involvement, 162–163 secondary skin involvement, 151–153
- Mast cell (MC) skin density, morphea pathogenesis, 58
- Max-Joseph spaces, lichenoid dermatitis, 47
- Mechlorethamine, cutaneous T cell lymphoma therapy, 20–21
- MEL1S gene, adult T cell leukemia/lymphoma, 321
- Methotrexate-associated lymphoproliferative disease: borderline CD30-positive lymphoproliferative disorders, 445, 467 Epstein-Barr virus and, 388–389

- 8-Methoxypsoralen (8-MOP), cutaneous T cell lymphoma therapy, 15–16
- Mixed cell follicle center cell lymphoma, case studies, 178–190
- Mixed connective tissue disease (MCTD): lichenoid dermatitis, 49–51 morphea histopathology, 57
- Molecular profile:
- alopecia mucinosa, 134
 - angioid immunoblastic lymphadenopathy, 332–333
 - atypical lymphocytic lobular panniculitis, 108, 134–135, 137
 - B-cell chronic lymphocytic leukemia, 227
 - CD8 pseudolymphoma, 348
 - CD30-positive lymphoproliferative disease, 468–470
 - cutaneous T cell dyscrasias, 126–137
 - clonally restricted endogenous epitheliotropic manifestation, 126
 - diffuse large B cell lymphoma, 196
 - Epstein-Barr virus-associated lymphoproliferative disease, 383
 - eruptive dermatofibromas, 165–166
 - follicle center cell lymphoma, 176, 190
 - follicular mucinosis, 105–106
 - $\gamma\delta$ T cell lymphoma, 263
 - hydroa vacciniforme-like Epstein-Barr virus associations, 383
 - hypopigmented large plaque parapsoriasis, 130
 - hypopigmented mycosis fungoides, 97
 - idiopathic erythroderma, 103, 131
 - large plaque parapsoriasis, 132–133
 - lymphocyte-predominant Hodgkin lymphoma, 478
 - lymphomatoid papulosis, 443–444
 - lymphomatoid tissue reactions, 66–67
 - lymphoproliferative disorders:
 - basic principles, 25
 - immunoglobulin receptor structure, 26–27
 - PCR-based clonality assessment, 27–31
 - mantle cell lymphoma, 250, 256
 - marginal zone lymphomas, 145
 - mycosis fungoides, 292–296
 - nasal/extranodal natural killer cell/T cell lymphomas, 405
 - NK/T cell lymphomas, 409
 - pigmented purpuric dermatosis, 100, 129–130, 136
 - pityriasis lichenoides chronica (PLC), 127–128
 - precursor B lymphoblastic lymphoma/leukemia, 213–215
 - primary cutaneous Hodgkin lymphomas, 484–485
 - primary cutaneous plasmacytoma, 150
 - primary cutaneous small/medium sized pleomorphic T cell lymphoma, 315
 - subcutaneous panniculitis-like T cell lymphoma, 370, 375–376
 - syringolymphoid hyperplasia with alopecia, 104
 - T cell prolymphocytic leukemia (T-PLL), 230, 244–245
- Monoclonal antibodies: cutaneous T cell lymphoma therapy, 17–18
- mycosis fungoides, 294
- Monomorphic post-transplant lymphoproliferative disease (PTLD): diffuse large B cell lymphoma, 387
- Epstein-Barr virus association, 385–387
- marginal zone lymphoma, 387
- plasmablastic lymphoma variant, 386–387
- Morbilliform viral exanthem and drug eruption, features and pathology, 44
- Morphea: clinical features and pathology, 56–57
- histopathology, 57
- pathogenesis, 57–58
- Mosquito bite hypersensitivity, hydroa vacciniforme-like Epstein-Barr virus associations, 382–384
- Mucosal associated lymphoma (MALT)-like lymphoma, clinical features, 141–142
- Multilobated peripheral T cell lymphoma, differential diagnosis, 305
- MUM-1/IRF₄ marker, diffuse large B cell lymphoma, 192–199
- MUM1 myeloma antigen, follicle center cell lymphoma, and diffuse large cell B cell lymphoma 177
- MYC amplification and translocation, trisomy 8, 11–12
- MYC Break apart Probe, defined, 12
- MYC IgH Fusion Probe, defined, 12
- Mycoplasma pneumoniae*, erythema multiforme pathogenesis, 42
- Mycosis fungoides:
 - architecture of, 277–278, 280–285
 - case studies, 290–291
 - CD8 variant, 355
 - clinical features, 267–271
 - extracutaneous dissemination, 271
 - patch stages, 268–270
 - plaque stage, 270, 277
 - tumor stage, 270–271
 - cutaneous T cell lymphoma therapy, 14–15
 - cytogenetic studies, 292–296
 - cytomorphology, 282–285
 - defined, 267
 - demographics, 267
 - drug eruptions:
 - clinical features, 64–65
 - histopathology, 65–66
 - molecular profile, 66–67
 - pathogenesis, 67–68
 - phenotypic profile, 66
 - extracutaneous involvement, 285–289
 - cytogenetic abnormalities, 288
 - gene rearrangement profile, 288
 - pathogenesis, 288–289
 - phenotypic profile, 286–288
 - histopathology, 276–277
 - historical evolution, 267
- hypopigmented lesions, 96–97
- molecular profiles, 292–296
- morphology/light microscopic findings, 276–285
- tumor staging, 275, 284–285, 290–291
- variants, 271–285
 - adnexotropic, 272
 - in childhood, 271–272
 - granulomatous slack skin, 273
 - papuloerythroderma, 271
 - Sézary syndrome, 273–285
 - Woringer-Kolopp disease, 272–273
- Mycosis fungoides (MF), lymphomatoid tissue reactions, 63–64
- Myelodysplastic syndrome, primary pleomorphic T cell lymphoma, 303
- Myelomonocytic markers, defined, 10
- Narrowband UVB, cutaneous T cell lymphoma therapy, 22
- Nasal/extranodal NK cell lymphomas:
 - aggressive variant, 403–406
 - blastic/blastoid neoplasm, 406
 - case studies, 410–424
 - CD4 subset, 408–409
 - cell biology, 401–406
 - chronic granular lymphocytosis/large granular cell leukemia, 407–408
 - epidemiology, 399–401
 - Epstein-Barr virus, 406–409
 - panniculitis-like variants, 406–407
- Natural killer (NK) cells:
 - CD8 T cell lymphoproliferative disease, 344–345
 - Epstein-Barr virus, 381
 - markers, 9
 - nasal/extranodal NK T cell lymphomas:
 - aggressive variant, 403–406
 - blastic/blastoid neoplasm, 406
 - case studies, 410–424
 - CD4 subset, 408–409
 - cell biology, 401–406
 - chronic granular lymphocytosis/large granular cell leukemia, 407–408
 - epidemiology, 399–401
 - Epstein-Barr virus, 406–409
 - panniculitis-like variants, 406–407
 - subcutaneous panniculitis-like T cell lymphoma, 368–371
- Nervous system involvement, mycosis fungoides, 285–286
- Nickel allergeris, spongiotic dermatitis, 33–34
- Nodular sclerosis, classical Hodgkin lymphoma, 477
- Nonscarring discoid lupus erythematosus, clinical features and pathology, 55–56
- NPM-ALK hybrid protein, anaplastic large cell lymphoma, 449
- Nuclear factor (NF) pathways, lymphocyte-predominant Hodgkin lymphoma, 479

- Null cell phenotypes, anaplastic large cell lymphoma, 449
- Nummular eczema, pathology and diagnosis, 38
- Ofuji papuloerythroderma, clinical features, 271–272
- Oncogenes, marginal zone lymphomas, 147
- ORAL disease, plasmablastic lymphoma variant, 386–387
- p53 system, mycosis fungoides, 288–289
- Pagetoid reticulosis, clinical features, 272–273, 280–285
- Palisading granulomatous drug reaction, clinical features, 64–65
- Panniculitis-like T-cell lymphoma: case study, 74
CD56 positivity, 406–407
 $\gamma\delta$ T cell lymphoma and, 265
- Papuloerythroderma, clinical features, 271–272
- Paraffin embedded tissue, classification, 10–11
- Parakeratotic scale, allergic contact dermatitis, 34–35
- Parapsoriasis:
epidemiology, 94–95
hypopigmented large plaque parapsoriasis, 96–97
- Parvovirus B19, systemic lupus erythematosus and, 45
- Patch formation, mycosis fungoides, 268–270, 278–279
- Pathogenesis, hydroa vacciniforme-like Epstein-Barr virus associations, 384
- Paucicellular necrobiotic process, diffuse large cell B lymphoma, 195
- Pautrier's microabscess:
adult T cell leukemia/lymphoma, 319–320
mycosis fungoides, 280–285
- Pediatric variant, mycosis fungoides, 271–272
- Peripheral T cell lymphoma:
CD8 T cell lymphoproliferative disease, 363
classification, 300–303
- Perivascular lymphocytic infiltrates, histopathology, 54
- Perry-Romberg syndrome, morphea pathogenesis, 57
- Phenotypic profile:
adult T cell leukemia/lymphoma, 320
anaplastic large cell lymphoma, 448–449
angiimmunoblastic lymphadenopathy, 331–332
atypical lymphocytic lobular panniculitis, 108
B-cell chronic lymphocytic leukemia (B-CLL), 227
borderline CD30-positive lymphoproliferative disorders, 445
- Castleman's disease, 148
- CD8 pseudolymphoma, 348
- CD8 T cell lymphoproliferative disease, 346
- CD-30 positive large B cell lymphoma, 450
- diffuse large cell B lymphoma, 195–196
- Epstein-Barr virus-associated lymphoproliferative disease, 383
- follicle center cell lymphoma, 176
- $\gamma\delta$ T cell lymphoma, 262
- hydroa vacciniforme-like Epstein-Barr virus associations, 383
- hypopigmented mycosis fungoides, 97
- idiopathic erythroderma, 103
- intravascular lymphoma, 220–221
- lymphocyte-predominant Hodgkin lymphoma, 478
- lymphocytoma cutis assessment, 71
- lymphomatoid papulosis, 443–444
- mantle cell lymphoma, 249–250
- marginal zone lymphomas, 144–145
- mycosis fungoides, 286–288
- nasal/extranodal natural killer cell/T cell lymphomas, 401, 404–405
- NK/T cell lymphomas, CD 4 subset, 408
- pigmented purpuric dermatosis, 100
- pityriasis lichenoides chronica, 102
- primary cutaneous plasmacytoma, 150
- primary cutaneous small/medium sized pleomorphic T cell lymphoma, 304–305
- subcutaneous panniculitis-like T cell lymphoma, 370
- syringolymphoid hyperplasia with alopecia, 104
- T cell prolymphocytic leukemia (T-PLL), 229–230
- Photoallergic lichenoid dermatitis, 37–38
- Photodynamic therapy (PDT), cutaneous T cell lymphoma, 22
- Phototherapy, cutaneous T cell lymphoma, 21–22
- Pigmented purpuric dermatosis (PPD):
case study, 112–115
clinical features, 97–100
light microscopic findings, 99–100
molecular profile, 129–130, 136
- Pilotropic T cell dyscrasia: 105, 118–119
- PIM proto-oncogenes, diffuse large B cell lymphoma, 197
- Pityriasis lichenoides chronica (PLC):
case study, 109–111
clinical features, 100–103
molecular profile, 127–128
- Pityriasis lichenoides et varioliformis acuta (PLEVA), clinical features, 100–103
- Pityriasis rosea, pathology and diagnosis, 36–37
- Plaque formation, mycosis fungoides, 270, 277–279
- Plasmablastic lymphoma, Epstein-Barr virus association, 386–387, 390–391, 394
- Plasma cell markers, defined, 9
- Plasmacytic hyperplasia, Epstein-Barr virus association, 385, 392–393
- Plasmacytic marginal zone lymphoma, monomorphic post-transplant lymphoproliferative disease, 387
- Plasmacytoma, primary cutaneous manifestations, 149–150
- Platelet-derived growth factor (PDGF), morphea pathogenesis, 58
- Pleomorphic small/medium sized T cell lymphoma:
case studies, 306–314
classification, 303–304
clinical features, 300–303
cytogenetics, 304
differential diagnosis, 305
phenotypic profile, 304–305
- POEMS syndrome (Polyneuropathy, osteosclerotic bone lesions, endocrinopathy, monoclonal gammopathy):
case study, 169
Castleman's disease, 148–149
- POL gene, herpes-associated erythema multiforme pathogenesis, 42
- Polymerase chain reaction (PCR):
clonality determination and detection, 27–31
limitations of, 30–31
results evaluation, 29–30
- lymphoproliferative disorders diagnosis, basic principles, 25
mycosis fungoides, 288
pityriasis rosea, 36–37
- Polymorphic post-transplant lymphoproliferative disease (PTLD), Epstein-Barr virus association, 385
- Polymorphous light eruption (PMLE), type IV immune reaction, 52–54
- Popcorn cell morphology, lymphocyte-predominant Hodgkin lymphoma, 477–478
- Porphyria cutanea tarda, morphea histopathology, 57
- Post-transplant lymphoproliferative disease (PTLD):
anaplastic large cell lymphoma, 454–455
Epstein-Barr virus association, 384–387
lymphomatoid granulomatosis, 432–433
T cell disorder, 387–388
- Precursor B lymphoblastic lymphoma/leukemia:
clinical features, 198–199
cytogenetics, 200
differential diagnosis, 200–202
immunophenotype, 199–200
molecular and cytogenetic studies, 213–215
pathology, 199
- Pregnancy, papules of, 39

- Primary cutaneous lymphomas:
- B cell lymphoma, angioimmunoblastic lymphadenopathy, 331–332
 - diffuse large B cell lymphoma:
 - classification, 194
 - clinical features, 192–194
 - cytogenetics, 196
 - differential diagnosis, 197–198
 - molecular studies, 196
 - pathogenesis, 196–197
 - pathology, 194–195
 - phenotype, 195–196
 - EORTC classification, 4–6
 - epidermotropic cytotoxic lymphoma, 349–354
 - Epstein-Barr virus, 381
 - follicle center cell lymphoma:
 - clinical features, 173–174
 - cytogenetics, 177, 190
 - large cell type, 181–183
 - mixed cell case vignettes, 178–180, 184–189
 - molecular studies, 176, 190
 - pathogenesis, 176–177
 - pathology, 174–175
 - phenotypic profile, 176
 - prognosis, 177
 - $\gamma\delta$ T cell lymphoma:
 - case studies, 264–265
 - clinical features, 259–261
 - molecular studies, 263
 - morphology, 261–262
 - phenotype, 262
 - ultrastructural analysis, 263
 - Hodgkin lymphoma:
 - case studies, 480–483
 - classic subtypes, 477
 - clinical features, 475–476
 - cytogenetics, 478
 - histogenesis, 478–479
 - lymphocyte-predominant variant, 477
 - molecular and phenotype profiles, 478
 - large cell lymphoma, 203–205
 - CD30-positive B cell variant, 450–451
 - lymphoblastic lymphoma, 209–210
 - lymphomatoid granulomatosis, 431–433
 - NK/T cell lymphomas, 421–422
 - precursor B lymphoblastic lymphoma/leukemia:
 - clinical features, 198–199
 - cytogenetics, 200
 - differential diagnosis, 200–202
 - immunophenotype, 199–200
 - pathology, 199
 - small/medium sized pleomorphic T cell lymphoma:
 - case studies, 306–314
 - classification, 303–304
 - clinical features, 300–303
 - cytogenetics, 304
 - differential diagnosis, 305
 - phenotypic profile, 304–305
 - Primary cutaneous plasmacytoma, clinical features, 149–150
 - Primary cutaneous plasmacytosis, clinical features, 71–72
 - Primer design:
 - immunoglobulin H, 27
 - T-cell receptor- β structure, 27–29
 - Polymorphous leukocytoclastic dermatitis, CD8 T cell lymphoproliferative disease, 347
 - Pruritic urticarial plaques, features and pathology, 39
 - Pseudoepitheliomatous hyperplasia, CD8 T cell lymphoproliferative disease, 346
 - Pseudolymphoma, CD8 T cell lymphoproliferative disease, 348, 360–361
 - Pseudomycosis fungoides (pseudo-MF), drug eruptions, 64–65
 - lichenoid features, 76–77
 - Psoralen plus UVA exposure (PUVA), cutaneous T cell lymphoma therapy, 21–22
 - Purine analogs, cutaneous T cell lymphoma therapy, 18
 - Radiation therapy, cutaneous T cell lymphoma, 22
 - Reactive clonal lymphomatoid dermatitis of memory and activated T cells, lymphomatoid tissue reactions, 68
 - Recalcitrant dermatitis, mycosis fungoides, 296
 - Reed-Sternberg cells:
 - lymphocyte-predominant Hodgkin lymphoma, 477–478
 - lymphomatoid papulosis, 443–444
 - primary cutaneous Hodgkin lymphomas, molecular and cytogenetic profile, 484–485
 - Renal involvement, mycosis fungoides, 285
 - Restricted T cell repertoire, PCR clonality determination and detection, 29–30
 - Retinoids, cutaneous T cell lymphoma therapy, 16–17
 - topical agents, 21
 - Reverse transcriptase in situ hybridization, defined, 11
 - Reverse transcriptase polymerase chain reaction (RT-PCR):
 - lymphomatoid lupus erythematosus, 69
 - lymphomatoid papulosis, 444
 - Reversible lymphoid syrcasia, lymphomatoid tissue reactions, 68
 - Reversible T cell dyscrasia, lymphomatoid tissue reactions, 63–64
 - Revised European-American Classification of Lymphoid Neoplasms (REAL) classification:
 - lymphoma classification, 2–6
 - nasal/extranodal natural killer cell/T cell lymphomas, 399–401
 - Scleroderma, morphea histopathology, 57
 - Sclerodermatomyositis (SDM), lichenoid dermatitis, 49–51
 - Sclerosing immunocytoma, marginal zone lymphomas, 144–145
 - Seborrheic dermatitis, nummular eczema, differential diagnosis, 38
 - Sensitivity, clonality assessment by PCR, 30–31
 - Sézary syndrome (SS):
 - clinical features, 273–285
 - cutaneous T cell lymphoma, 14
 - extracorporeal photopheresis therapy, 15–16
 - idiopathic erythroderma, 102–103
 - morphology/light microscopic findings, 276–285
 - mycosis fungoides, clinical features, 267–268
 - phenotypic profiles, 286–288
 - prognosis, 275–276
 - staging, 275–276
 - Single-strand conformation polymorphism (SSCP), lymphomatoid lupus erythematosus, 69
 - Skin-directed therapies, cutaneous T cell lymphoma, 20–22
 - Skin disorders:
 - anaplastic large cell lymphoma, 445–450
 - B cell lymphoproliferative disorder, marginal zone lymphoma:
 - clinical features, 141–142
 - cytogenetic abnormalities, 147
 - differential diagnosis, 147–148
 - molecular studies, 145
 - pathogenesis, 145–146
 - pathology, 142–144
 - phenotypic profile, 144–145
 - CD8 T cell lymphoproliferative disease:
 - basic characteristics, 343–345
 - case studies, 349–363
 - drug therapy and, 348
 - histomorphology, 345–346
 - lymphomatoid papulosis variants, 346–347
 - phenotypic profile, 346
 - primary cutaneous lymphoma, 343–345
 - pseudolymphomas, 348
 - CD30-positive lymphoproliferative disease, 463–464
 - chronic lymphocytic leukemia:
 - skin infiltration, 231–233, 236–238
 - T-cell type, 241
 - cutaneous T cell lymphoma:
 - granulomatous slack skin, 273
 - skin-directed therapies, 20–22
 - hydroa vacciniforme-like Epstein-Barr virus associations, 382–384
 - Jessner's lymphocytic infiltrate of the skin, 58–59
 - marginal zone lymphoma, 151–153
 - mast cell skin density, morphea pathogenesis, 58

- Skin disorders: (*Continued*)
 mycosis fungoides, granulomatous slack skin, 273
 NK/T cell lymphomas, 410–412
 primary cutaneous Hodgkin lymphomas, 475–479
 T cell prolymphocytic leukemia, 241
- Sleeve-like morphology:
 erythema annulare centrifugum, 39–40
 polymorphous light eruption, 53–54
- Small plaque parapsoriasis, features and pathology, 39
- Spiegler-Fendt lymphocytic infiltrate, lymphocytoma cutis, 70–71
- Spongiotic reactions:
 allergic contact dermatitis, 33–37
 tissue reactions, 37–38
- Squamous cell carcinoma, chronic lymphocytic leukemia, 234–235
- Staging evaluation, cutaneous T cell lymphoma, 14
- Stevens-Johnson syndrome, erythema multiforme, 41–42
- Subacute cutaneous lupus erythematosus (SACLE):
 lichenoid dermatitis, 48–51
 lymphomatoid tissue reactions, 68–69
- Subcutaneous panniculitis-like T cell lymphomas:
 case studies, 372–378
 clinical features, 366–369
 differential diagnosis, 370–374
 molecular studies, 370
 morphology, 369–370
 phenotype, 370
- Suberoylanilide hydroxamic acid (SAHA), cutaneous T cell lymphoma therapy, 20
- Surveillance, Epidemiology and End Results (SEER) program, mycosis fungoides demographics, 267
- Syphilis, lichen planus eruptions, 48
- Syringolymphoid hyperplasia with alopecia (SLHA), clinical features, 103–104
- Syngotropic cutaneous T cell lymphoma, clinical features, 272
- Systemic lupus erythematosus:
 antibody-dependent cellular immunity, 45
 classification of, 45
 erythema multiforme, 41–42
 histopathology, 50
 lichenoid dermatitis, 49–51
- T cell antibodies, classification, 8–9
- T cell dyscrasias:
 adnexotropic manifestation, 122–123
 lymphomatoid granulomatosis, 432–433
 lymphomatoid tissue reactions, 66
 subcutaneous panniculitis-like T cell lymphoma, 370–371
- T-cell intracellular antigen 1 (TIA-1):
 nasal/extranodal natural killer cell/T cell lymphomas, 402
 subcutaneous panniculitis-like T cell lymphoma, 370
 T cell lymphomas. *See also* Mycosis fungoides
 angioimmunoblastic variant:
 case studies, 334–339
 clinical features, 329–331
 light microscopic findings, 331
 molecular studies, 332–333
 pathogenesis, 333
 phenotypic profile, 331–332
- CD8 T cell lymphoproliferative disease:
 basic characteristics, 343
 case studies, 349–363
 drug therapy and, 348
 histomorphology, 345–346
 lymphomatoid papulosis variants, 346–347
 phenotypic profile, 346
 primary cutaneous lymphoma, 343–345
 pseudolymphomas, 348
- $\gamma\delta$ T cell lymphoma:
 case studies, 264–265
 clinical features, 259–261
 molecular studies, 263
 morphology, 261–262
 phenotype, 262
 ultrastructural analysis, 263
- intravascular lymphoma, 219–223
- lymphomatoid tissue reactions, basic principles, 63–64
 molecular profile, 66–67
- nasal/extranodal NK cell variants:
 aggressive variant, 403–406
 blastic/blastoid neoplasm, 406
 case studies, 410–424
 CD4 subset, 408–409
 cell biology, 401–406
 chronic granular lymphocytosis/large granular cell leukemia, 407–408
 epidemiology, 399–401
 Epstein-Barr virus, 406–409
 panniculitis-like variants, 406–407
 panniculitis-like T-cell lymphoma, 74
 precursor lesions, cutaneous lymphoid dyscrasia, 93–108
- subcutaneous panniculitis-like variant:
 case studies, 372–378
 clinical features, 366–369
 differential diagnosis, 370–371
 molecular studies, 370
 morphology, 369–370
 phenotype, 370
- T cell prolymphocytic leukemia (T-PLL):
 case studies, 239–240
 CD8 T cell lymphoproliferative disease, 347
 case study, 356–357
 clinical features, 228–229
 cutaneous T cell lymphoma therapy, 18
 cytogenetic abnormalities, 230
 differential diagnosis, 230, 242–243
 pathology, 229
 phenotypic profiles, 229–230
 skin involvement, 241
- T-cell receptor- β marker:
 primer design, 27–28
 receptor structure, 27
- T-cell receptor- γ marker:
 defined, 8
- T-cell receptors (TCR):
 anaplastic large cell lymphoma, 448–449
 cutaneous T cell lymphoma and rearrangement of, 15
 lymphomatoid tissue reactions, 63–64
 molecular diagnostic techniques, 25
 nasal/extranodal natural killer cell/T cell lymphomas, epidemiology, 401–402
- T-cell-restricted intracellular antigen (TIA), CD8 T cell lymphoproliferative disease, 344
- TCL-1 oncogene:
 adult T cell leukemia/lymphoma, 321
 T cell prolymphocytic leukemia (T-PLL), 230
- TCR-1 antibody, defined, 8
- Terminal deoxynucleotidyl transferase (TdT), precursor B lymphoblastic lymphoma/leukemia, 199–200
- Th2 cytokines:
 CD8 T cell lymphoproliferative disease, 345
 cutaneous T cell lymphoma therapy, 14–15
- T helper cells, allergic contact dermatitis, 34
- Tissue eosinophilia, papuloerythroderma, 271
- Tissue growth factor (TGF), morphea pathogenesis, 57–58
- Toll-like receptors (TLRs):
 cutaneous T cell lymphoma therapy, agonists and cytokines, 19
 primary cutaneous plasmacytoma, 150
- Topical corticosteroids, cutaneous T cell lymphoma therapy, 20
- Total skin electron beam (TSEB) therapy, cutaneous T cell lymphoma, 22
- Toxic epidermal necrolysis, erythema multiforme pathogenesis, 42
- Transforming growth factor- β (TGF- β):
 anaplastic large cell lymphoma, 450
 morphea pathogenesis, 58
- Trimetrexate (TMTX), cutaneous T cell lymphoma therapy, 18
- Trisomy 3, marginal zone lymphomas, 147
- Trisomy 8, MYC amplification and translocation, 11–12
- Tumid lupus erythematosus, clinical features and pathology, 55–56
- Tumor necrosis factor- α (TNF- α), cell-poor vacuolar interface dermatitis, 44
- Tumor staging, mycosis fungoides, 270–271, 283–285, 290–291
- Tumor suppressor genes, mycosis fungoides, 289

- Ultrastructural analysis, $\gamma\delta$ T cell lymphoma, 263
- Variable heavy (VH) segments, immunoglobulin receptor structure, 26–27
- Vascular lymphomatoid tissue reactions: clonality assessment, 84 lymphomatoid granulomatosis, 432–436
- V-D-J rearrangement, immunoglobulin H Receptor structure, 26–27
- Viral-associated lymphomatoid dermatitis, clinical features, 70
- Viral thymidine kinase (vTK) assay: defined, 11 Epstein-Barr virus-associated B cell lymphoma, 388–389
- Weber-Christian disease, subcutaneous panniculitis-like T cell lymphoma, 370–371, 377–378
- WHO classification: diffuse large B cell lymphoma, 193–194 of lymphoma, 2–6
- nasal/extranodal natural killer cell/T cell lymphomas, 399–401
- Sézary syndrome (SS), 274–285
- subcutaneous panniculitis-like T cell lymphoma, 366–368
- Woringer-Kolopp disease, clinical features, 272–273
- Zoon's balanitis/vulvitis, primary cutaneous plasmacytosis, 71–72